Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

BUY
$0.84 - $1.22 $254 - $369
303 Added 3.57%
8,784 $10,000
Q3 2023

Nov 13, 2023

BUY
$0.82 - $1.42 $246 - $427
301 Added 3.68%
8,481 $7,000
Q2 2023

Aug 04, 2023

BUY
$1.09 - $9.93 $8,916 - $81,227
8,180 New
8,180 $9,000
Q2 2022

Aug 12, 2022

SELL
$2.21 - $5.56 $17,456 - $43,918
-7,899 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$5.07 - $13.68 $2,818 - $7,606
-556 Reduced 6.58%
7,899 $40,000
Q4 2021

Feb 11, 2022

BUY
$11.91 - $17.0 $51,403 - $73,372
4,316 Added 104.28%
8,455 $109,000
Q3 2021

Nov 12, 2021

SELL
$13.21 - $20.91 $250 - $397
-19 Reduced 0.46%
4,139 $62,000
Q2 2021

Aug 13, 2021

BUY
$15.08 - $20.3 $62,702 - $84,407
4,158 New
4,158 $65,000

Others Institutions Holding RAIN

About Rain Therapeutics Inc.


  • Ticker RAIN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,837,400
  • Description
  • Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...
More about RAIN
Track This Portfolio

Track American International Group, Inc. Portfolio

Follow American International Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on American International Group, Inc. with notifications on news.